Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163162 · ClinicalTrials.gov registry record · Phase 4
The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT01163162 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 16 participants.
The verdict
NCT01163162, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to study the effects of Paricalcitol (Zemplar) on kidney functioning. The investigators hypothesize that the increase in serum creatinine observed in recent paricalcitol trials is a function of reduced creatinine secretion and not an actual reduction in kidney function. 16 patients will have kidney function measured via iothalamate clearance at baseline, after 7 days of paricalcitol treatment and after 7 days of being washed off the paricalcitol.
Interventions
- DRUG Paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163162
The ClinicalTrials.gov registry entry for NCT01163162 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paricalcitol is the first listed.
NCT01163162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163162 about?
NCT01163162 is a clinical study titled "The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate". The purpose of this study is to study the effects of Paricalcitol (Zemplar) on kidney functioning. The investigators hypothesize that the increase in serum creatinine observed in recent paricalcitol trials is a function of reduced creatinine secretion and not an actual reduction in kidney function. ...
What is the current status of trial NCT01163162?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2010-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01163162?
The interventions under investigation include: Paricalcitol (DRUG).
Who is sponsoring clinical trial NCT01163162?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.